Edward Kim

Medicine · Health Sciences

32h-index3.8kcitations92works0.82yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(10), RNA modifications and cancer(9), Melanoma and MAPK Pathways(9), Cancer, Hypoxia, and Metabolism(8), Adrenal and Paraganglionic Tumors(8)

Publications91 total

SLIT3 INDUCED WITH LPS STIMULATION PROMOTES PHAGOCYTOSIS AND AMELIORATES INFLAMMATION IN MACROPHAGE
Annals of Allergy Asthma & Immunology·2025
Current evidence for neoadjuvant therapy in resectable pancreatic cancer
AME Clinical Trials Review·2024Open Access
Proceedings of the 1st biannual bridging the gaps in lung cancer conference
The Oncologist·2024· 1 citedOpen Access
1398TiP Be6A Lung-01, a phase III study of sigvotatug vedotin (SV), an investigational antibody-drug conjugate (ADC) versus docetaxel in patients (pts) with previously treated non-small cell lung cancer (NSCLC)
Annals of Oncology·2024· 2 cited
Large Language Models Reshaping Molecular Biology and Drug Development
SSRN Electronic Journal·2024· 1 citedOpen Access
Abstract 2178: Circulating tumor DNA (ctDNA) correlates closely with tumor necrosis and relapse-free survival (RFS) in hepatocellular carcinoma (HCC) patients treated with perioperative cemiplimab
Cancer Research·2023· 3 cited
Data from Global Assessment of Genetic Variation Influencing Response to Retinoid Chemoprevention in Head and Neck Cancer Patients
2023Open Access
Perspective on This Article from Global Assessment of Genetic Variation Influencing Response to Retinoid Chemoprevention in Head and Neck Cancer Patients
2023Open Access
Perspective on this Article from Cyclic AMP-Responsive Element Binding Protein– and Nuclear Factor-κB–Regulated CXC Chemokine Gene Expression in Lung Carcinogenesis
2023Open Access
Perspective on this Article from Cyclic AMP-Responsive Element Binding Protein– and Nuclear Factor-κB–Regulated CXC Chemokine Gene Expression in Lung Carcinogenesis
2023Open Access
Perspective on This Article from Global Assessment of Genetic Variation Influencing Response to Retinoid Chemoprevention in Head and Neck Cancer Patients
2023Open Access
Data from Global Assessment of Genetic Variation Influencing Response to Retinoid Chemoprevention in Head and Neck Cancer Patients
2023Open Access
Supplementary Data from MITF Expression Predicts Therapeutic Vulnerability to p300 Inhibition in Human Melanoma
2023Open Access
Data from Genetic Variants in the PI3K/PTEN/AKT/mTOR Pathway Predict Head and Neck Cancer Patient Second Primary Tumor/Recurrence Risk and Response to Retinoid Chemoprevention
2023Open Access
Data from Anti-DLL4 Has Broad Spectrum Activity in Pancreatic Cancer Dependent on Targeting DLL4-Notch Signaling in Both Tumor and Vasculature Cells
2023Open Access
Supplementary Data from A Five-Gene and Corresponding Protein Signature for Stage-I Lung Adenocarcinoma Prognosis
2023Open Access
Supplementary Data from MITF Expression Predicts Therapeutic Vulnerability to p300 Inhibition in Human Melanoma
2023Open Access
Data from Anti-DLL4 Has Broad Spectrum Activity in Pancreatic Cancer Dependent on Targeting DLL4-Notch Signaling in Both Tumor and Vasculature Cells
2023Open Access
Supplementary Data from MITF Expression Predicts Therapeutic Vulnerability to p300 Inhibition in Human Melanoma
2023Open Access
Supplementary Data from MITF Expression Predicts Therapeutic Vulnerability to p300 Inhibition in Human Melanoma
2023Open Access
page 1 of 5Next →

Frequent Co-authors

Roderick Clifton‐Bligh(9), Anthony J. Gill(7), Waun Ki Hong(6), Trisha Dwight(6), Diana E. Benn(5), Stephen G. Young(4), Margaret R. Spitz(4), J. Jack Lee(4), Fadlo R. Khuri(4), Reuben Lotan(4), Rhoda M. Alani(3), Steven Clarke(3), Bruce G. Robinson(3), Scott M. Lippman(3), Hushan Yang(3), Rebecca Spain(3), Sonemany Salinthone(3), Vincenzo Costanzo(2), Kirsten Robertson(2), Domenico Grieco(2)